Serotonin, But Not N -Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Hallucinogens mediate many of their psychoactive effects by activating serotonin 2A receptors (5-HT 2A R). Although serotonin is the cognate endogenous neurotransmitter and is not considered hallucinogenic, metabolites of serotonin also have high affinity at 5-HT 2A R and can induce hallucinations in humans. Here we report that serotonin differs from the psychoactive N -methyltryptamines by its ability to engage a β-arrestin2-mediated signaling cascade in the frontal cortex. Serotonin and 5-hydroxy- l -tryptophan (5-HTP) induce a head-twitch response in wild-type (WT) mice that is a behavioral proxy for 5-HT 2A R activation. The response in β-arrestin2 knock-out (βarr2-KO) mice is greatly attenuated until the doses are elevated, at which point, βarr2-KO mice display a head-twitch response that can exceed that of WT mice. Direct administration of N -methyltryptamines also produces a greater response in βarr2-KO mice. Moreover, the inhibition of N -methyltransferase blocks 5-HTP-induced head twitches in βarr2-KO mice, indicating that N -methyltryptamines, rather than serotonin, primarily mediate this response. Biochemical studies demonstrate that serotonin stimulates Akt phosphorylation in the frontal cortex and in primary cortical neurons through the activation of a β-arrestin2/phosphoinositide 3-kinase/Src/Akt cascade, whereas N -methyltryptamines do not. Furthermore, disruption of any of the components of this cascade prevents 5-HTP-induced, but not N -methyltryptamine-induced, head twitches. We propose that there is a bifurcation of 5-HT 2A R signaling that is neurotransmitter and β-arrestin2 dependent. This demonstration of agonist-directed 5-HT 2A R signaling in vivo may significantly impact drug discovery efforts for the treatment of disorders wherein hallucinations are part of the etiology, such as schizophrenia, or manifest as side effects of treatment, such as depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821 · cited 1×
“…accompanied by hallucinations and is particularly problematic when selective serotonin reuptake inhibitors are taken with monoamine oxidase inhibitors (Insel et al., 1982; Sternbach, 1991; Boyer and Shannon, 2005) when serotonin, and presumably N-methyltryptamine, levels would be greatly elevated.”
BackgroundPredicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667 · cited 2×
“Hallucinogens act at the 5-HT2AR to produce a distinct head-twitch response in rodents (Corne and Pickering, 1967) that is prevented by genetic ablation or pharmacological antagonism of the 5-HT2AR (Willins and Meltzer, 1997; González-Maeso et al., 2007; Keiser et al., 2009).”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 4×
“Diverse ligands to the 5-HT2AR have been shown to differentially activate downstream signaling cascades both in vitro and in vivo (Berg et al., 1998; Kurrasch-Orbaugh et al., 2003; González-Maeso et al., 2007; Schmid et al., 2008).”
BackgroundInfluentialJakab, R. L., & Goldman-Rakic, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.735 · Cited by 536 · cited 2×
“Introduction The serotonin 2A receptor (5-HT2AR) is highly expressed on pyramidal neurons in the frontal cortex and has been implicated in several mental health disorders, including schizophrenia, anxiety, and depression (Jakab and Goldman-Rakic, 1998; Meltzer, 2002; Miner et al., 2003; Roth et al., 2004; Berg et al.,…”
BackgroundAghajanian, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00135-3 · Cited by 371 · cited 1×
“The 5-HT2AR is also the target of serotonergic hallucinogenic drugs (Aghajanian and Marek, 1999; Nichols, 2004).”
BackgroundNew Roles for β-Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors
Lefkowitz, R. J., Rajagopal, K., & Whalen, E. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.007 · Cited by 301 · cited 2×
“…scaffolding proteins that can either dampen or facilitate GPCR signaling and therefore may represent a key point at which receptor signaling may diverge in response to particular ligands (Luttrell and Lefkowitz, 2002; Lefkowitz et al., 2006; DeWire et al., 2007; Rajagopal et al., 2010).”
BackgroundGonzález-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
Miner, L. A. H., Backstrom, J. R., Sanders-Bush, E., & Sesack, S. R. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00580-8 · Cited by 216 · cited 2×
“Introduction The serotonin 2A receptor (5-HT2AR) is highly expressed on pyramidal neurons in the frontal cortex and has been implicated in several mental health disorders, including schizophrenia, anxiety, and depression (Jakab and Goldman-Rakic, 1998; Meltzer, 2002; Miner et al., 2003; Roth et al., 2004; Berg et al.,…”
BackgroundKurrasch‐Orbaugh, D. M., Parrish, J. C., Watts, V. J., & Nichols, D. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01921.x · Cited by 138 · cited 3×
“Diverse ligands to the 5-HT2AR have been shown to differentially activate downstream signaling cascades both in vitro and in vivo (Berg et al., 1998; Kurrasch-Orbaugh et al., 2003; González-Maeso et al., 2007; Schmid et al., 2008).”
BackgroundEffect of ring fluorination on the pharmacology of hallucinogenic tryptamines
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., Barker, E. L., & Nichols, D. E. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000339w · Cited by 131 · cited 1×
“It has previously been very difficult to delineate the distinct neuropharmacological effects produced by serotonin and its psychoactive metabolites in vivo because many of the biogenic amines have higher affinities than serotonin at the 5-HT2AR (Glennon and Gessner, 1979; Blair et al., 2000).”
BackgroundBufotenine: Toward an understanding of possible psychoactive mechanisms
McBride, M. C. (2000) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2000.10400456 · Cited by 74 · cited 2×
“In the brain, serotonin is a substrate for N-methyltransferases, enzymes that act to convert serotonin to N-methyltryptamines; these metabolites possess psychoactive properties and can be hallucinogenic in humans (Axelrod, 1962; Glennon and Gessner, 1979; Shulgin and Shulgin, 1997; McBride, 2000).”
Background
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors
Vargas, M. V., Dunlap, L. E., Dong, C., Carter, S. J., Tombari, R. J., Jami, S. A., Cameron, L. P., Patel, S. D., Hennessey, J. J., Saeger, H. N., et al. (2023) · Science · doi:10.1126/science.adf0435 · Cited by 489
Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling
Shukla, A. K., Xiao, K., & Lefkowitz, R. J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.06.003 · Cited by 418
The role of serotonin 5-HT2A receptors in memory and cognition
Zhang, G., & Stackman, R. W. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00225 · Cited by 382
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript and p38 MAP kinase), Akt, and phospholipase D (dependent on the small G protein ADPribosylation factor-1 (ARF1)) (Kurrasch-Orbaugh et al., 2003a; González-Maeso et al., 2007; Schmid and Bohn, 2010; Barclay et al., 2011).”
Background
Metadata
- Authors
- Schmid, C. L., & Bohn, L. M.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-10-06
- Volume
- 30
- Issue
- 40
- Pages
- 13513-13524
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1994495174
- Cited by
- 175
- References
- 12
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.